TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26219446

Group type: EXPERIMENTAL
Intervention: 12-week cognitive behavioral therapy based occupational therapy (OT-CBSM)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Home program (control group)
Number of subjects: 55
Study: 23726746

Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 98

Group type: COMPARATOR
Intervention: Untrained residents (control group)
Number of subjects: 98
Study: 22054017

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Number of subjects: 436

Group type: COMPARATOR
Intervention: Usual brief advice (control)
Number of subjects: 436
Study: 18434578

Group type: EXPERIMENTAL
Intervention: 150 mmol/L Ca rinse
Number of subjects: 13

Group type: COMPARATOR
Intervention: 12 mmol/L NaF rinse
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ca rinse followed by F rinse
Number of subjects: 13
Study: 17398039

Group type: EXPERIMENTAL
Intervention: Behavioral intervention designed to reduce behaviors associated with HIV and HCV transmission
Number of subjects: 3129

Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 3129
Study: 14725783

Group type: EXPERIMENTAL
Intervention: Computer‐assisted multimedia training course for intravenous injection
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 81
Study: 11739054

Group type: EXPERIMENTAL
Intervention: Staff Internist (SI) led intervention
Number of subjects: 44

Group type: COMPARATOR
Intervention: Resident Instructor (RI) led intervention
Number of subjects: 44
Study: 8996137

Group type: EXPERIMENTAL
Intervention: L‐PAM alone (10 mg/m2, 15 mg/m2, 17.5 mg/m2, 20 mg/m2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: L‐PAM plus WBH (at various doses)
Number of subjects: 16

Group type: COMPARATOR
Intervention: WBH alone
Number of subjects: 16
Study: 8355124

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Formula with 1290 mg/L calcium
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard formula with 545 mg/L calcium
Number of subjects: 59
Study: 2446463

Group type: EXPERIMENTAL
Intervention: Active ECT
Number of subjects: 11

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 11
Study: 31397179

Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone 30 mg daily
Number of subjects: 239

Group type: COMPARATOR
Intervention: Micronized vaginal progesterone (MVP) gel 90 mg daily
Number of subjects: 239
Study: 29100197

Group type: EXPERIMENTAL
Intervention: Family video message
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Nature video
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study: 27858072

Group type: EXPERIMENTAL
Intervention: Vitapex and minocycline hydrochloride
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (conventional root canal therapy)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Experimental group (Vitapex and minocycline hydrochloride)
Number of subjects: 120
Study: 26553836

Group type: EXPERIMENTAL
Intervention: Amiloride 10 mg daily
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 23672570

Group type: EXPERIMENTAL
Intervention: Perception of bronchoconstriction measured as slope of FEV(1) and Borg score
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Borg score at a 20% decrease in FEV(1) (PS(20))
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Repeatability of Borg scores
Number of subjects: 112
Study: 20496730

Group type: EXPERIMENTAL
Intervention: Acupuncture at Xuanzhong (GB 39) combined with Chinese herbs pyrogenic dressing therapy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Common acupuncture (Yanglingquan (GB 34), Kunlun (BL 60), etc.)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Common acupuncture
Number of subjects: 66
Study: 19117256

Group type: EXPERIMENTAL
Intervention: Reality female condom
Number of subjects: 233

Group type: COMPARATOR
Intervention: Prototype female condom (FC2)
Number of subjects: 233
Study: 16753251

Group type: EXPERIMENTAL
Intervention: Laypersons responding to a medical emergency (CPR/AED training)
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Laypersons responding in residential settings
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Females and non-native English speakers among lay responders
Number of subjects: 1243

Group type: EXPERIMENTAL
Intervention: Qualitative responses from lay responders
Number of subjects: 1243
Study: 14629771

Group type: EXPERIMENTAL
Intervention: Metronidazole for 10 days
Number of subjects: 39

Group type: COMPARATOR
Intervention: Ultrasound-guided needle aspiration with metronidazole
Number of subjects: 39
Study: 10735900

Group type: EXPERIMENTAL
Intervention: G‐CSF (lenogastrim) administered after each chemotherapy course
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: G‐CSF (lenogastrim) administered after R3 courses
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: G‐CSF (lenogastrim) administered after chemotherapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: G‐CSF (lenogastrim) vs non-G‐CSF group
Number of subjects: 67
Study: 8823852

Group type: EXPERIMENTAL
Intervention: SmithKline Beecham vaccine (Engerix‐B, 10 micrograms/dose)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Merck vaccine (Recombivax HB, 2.5 micrograms/dose)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 428
Study: 1603470

Group type: EXPERIMENTAL
Intervention: Cardioscint
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gamma camera
Number of subjects: 10
Study: 3881648

Group type: EXPERIMENTAL
Intervention: Overeating (+1000 kcal/m2 above isocaloric requirements)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Undereating (400 kcal/d)
Number of subjects: 6
Study: 30825395

Group type: EXPERIMENTAL
Intervention: High-frequency intervention (biweekly SMS for 6 months)
Number of subjects: 1362

Group type: EXPERIMENTAL
Intervention: Low-frequency intervention (monthly SMS for 6 months)
Number of subjects: 1362

Group type: COMPARATOR
Intervention: Control group (no SMS)
Number of subjects: 1362
Study: 30423575

Group type: EXPERIMENTAL
Intervention: Naloxone (1.6 mg or 3.2 mg q70 kg IV) with smoking-related cues
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone (1.6 mg or 3.2 mg q70 kg IV) with neutral cues
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo with smoking-related cues
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Naloxone (1.6 mg or 3.2 mg q70 kg IV)
Number of subjects: 20
Study: 27393604

Group type: EXPERIMENTAL
Intervention: BEATVIC training (body-oriented resilience training with elements of kickboxing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social activation (control condition)
Number of subjects: 0
Study: 24359298

Group type: EXPERIMENTAL
Intervention: Messages designed to discourage smokers from trying snus
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: High efficacy messages
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Low efficacy messages
Number of subjects: 1836

Group type: EXPERIMENTAL
Intervention: Anti-smokeless ads
Number of subjects: 1836
Study: 22768640

Group type: EXPERIMENTAL
Intervention: Increased boot weight
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: More flexible soles
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Boot weight
Number of subjects: 27
Study: 19793149

Group type: EXPERIMENTAL
Intervention: Robotic navigation (RN) guided approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional ablation approach
Number of subjects: 60
Study: 18447961

Group type: EXPERIMENTAL
Intervention: Duration of untreated psychosis (DUP)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Pre-morbid social adaptation
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Pre-morbid school adaptation
Number of subjects: 423
Study: 15808251

Group type: EXPERIMENTAL
Intervention: Brimonidine purite
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 31
Study: 12516106

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy using 3% ALA in Intrasite Gel applied topically for 3 hours.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 25
Study: 11739975

Group type: EXPERIMENTAL
Intervention: Middle cerebral artery (MCA) territory
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Basilar artery (BA) territory
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 23
Study: 9194010

Group type: EXPERIMENTAL
Intervention: Progressive relaxation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 0
Study: 1375059

Group type: EXPERIMENTAL
Intervention: Iodine deficiency disorders (IDD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selenium deficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thiocyanate overload from poorly detoxified cassava
Number of subjects: 0
Study: 2862514

Group type: EXPERIMENTAL
Intervention: Paracervical injection of vasopressin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29608680

Group type: EXPERIMENTAL
Intervention: Extended infusion (4 hours) of piperacillin-tazobactam or ceftazidime
Number of subjects: 105

Group type: COMPARATOR
Intervention: Bolus infusion (30 minutes) of piperacillin-tazobactam or ceftazidime
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Extended infusion (4 hours) of beta-lactams
Number of subjects: 105

Group type: COMPARATOR
Intervention: Bolus infusion (30 minutes) of beta-lactams
Number of subjects: 105
Study: 26351780

Group type: EXPERIMENTAL
Intervention: LY3023703 (30 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Celecoxib (400 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: LY3023703 (15 mg)
Number of subjects: 48
Study: 25038356

Group type: EXPERIMENTAL
Intervention: Optional home initiation of HIV care (including 2 weeks of ART if eligible)
Number of subjects: 16660

Group type: COMPARATOR
Intervention: Facility-based care
Number of subjects: 16660

Group type: EXPERIMENTAL
Intervention: Home initiation of HIV care
Number of subjects: 16660
Study: 22402733

Group type: EXPERIMENTAL
Intervention: Environmental modification (EM) program
Number of subjects: 2060

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 2060
Study: 20129825

Group type: EXPERIMENTAL
Intervention: 2 ng/ml GM‐CSF
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (without GM‐CSF)
Number of subjects: 73
Study: 18690630

Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealer (BVS)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ultrasonically coagulating shears (UCS)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Monopolar electrosurgery scissors (MES)
Number of subjects: 61
Study: 15979009

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) treatment for knee OA, 2h daily, 5 days per week for 6 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMF) treatment for patients <65 years
Number of subjects: 83
Study: 12917242

Group type: EXPERIMENTAL
Intervention: Bolus injection of 1 g meropenem
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 h infusion of 1 g meropenem
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 h infusion of 0.5 g meropenem
Number of subjects: 12
Study: 12352219

Group type: EXPERIMENTAL
Intervention: Carbonated water
Number of subjects: 21

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 21
Study: 10629385

Group type: EXPERIMENTAL
Intervention: Dihydroepiandrosterone (50 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 10150537

Group type: EXPERIMENTAL
Intervention: HRA report with counseling
Number of subjects: 161

Group type: COMPARATOR
Intervention: No HRA report or counseling (Control)
Number of subjects: 161
Study: 2178719

Group type: EXPERIMENTAL
Intervention: Silicone gel sheet containing Ofloxacin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Collagen sheet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ointment-impregnated gauze
Number of subjects: 20
Study: 7378115

Group type: EXPERIMENTAL
Intervention: Preparation A (hydrous solution, 1 mg F−/100 ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Preparation B (2 tablets at 0.5 mg F−)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Preparation C (1 NaF tablet with 1 mg F−)
Number of subjects: 12

Group type: COMPARATOR
Intervention: All preparations
Number of subjects: 12
Study: 6415745

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28690028

Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM) with or without intravenous immunoglobulin (IVIG)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIPC/TAZ) with or without intravenous immunoglobulin (IVIG)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MEPM or PIPC/TAZ
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MEPM + IVIG or PIPC/TAZ + IVIG
Number of subjects: 71
Study: 27315546

Group type: EXPERIMENTAL
Intervention: HAT (bevacizumab, trastuzumab, and paclitaxel)
Number of subjects: 84

Group type: COMPARATOR
Intervention: HA-HAT (trastuzumab and bevacizumab with paclitaxel after progression)
Number of subjects: 84

Group type: COMPARATOR
Intervention: HA-HAT (trastuzumab and bevacizumab)
Number of subjects: 84

Group type: COMPARATOR
Intervention: HA-HAT (bevacizumab and paclitaxel)
Number of subjects: 84
Study: 24942239

Group type: EXPERIMENTAL
Intervention: 75% sucrose solution
Number of subjects: 537

Group type: COMPARATOR
Intervention: 25% sucrose solution
Number of subjects: 537

Group type: COMPARATOR
Intervention: Sterile water
Number of subjects: 537
Study: 22893496

Group type: EXPERIMENTAL
Intervention: Periprostatic nerve block (Anesthesia group; n=120)
Number of subjects: 241

Group type: COMPARATOR
Intervention: No anesthesia (Control group; n=121)
Number of subjects: 241
Study: 20549829

Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel and carboplatin (TC) for 4 cycles every 3 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel and carboplatin (TC) for 4 cycles every 3 weeks + trastuzumab for HER2-positive tumors
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Achieving a pathologic complete response (pCR)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Achieving a clinical complete response (cCR)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Overall survival (OS) and recurrence-free survival (RFS) rates
Number of subjects: 74
Study: 18942601

Group type: EXPERIMENTAL
Intervention: Nitrous oxide / oxygen analgesia (NOA) with fasting
Number of subjects: 113

Group type: COMPARATOR
Intervention: Nitrous oxide / oxygen analgesia (NOA) without fasting
Number of subjects: 113
Study: 16155261

Group type: EXPERIMENTAL
Intervention: High-stearic acid diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-oleic acid diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-linoleic acid diet
Number of subjects: 45
Study: 12812212

Group type: EXPERIMENTAL
Intervention: Multi-slice/helical computed tomography (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-slice/helical CT
Number of subjects: 0
Study: 11044476

Group type: EXPERIMENTAL
Intervention: EMA IgG1 positivity in sera and a villous height/crypt depth ratio <3:1 as index of intestinal atrophy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gluten-free diet for 8-10 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (60 children with gastroenterological diseases other than CD and 63 healthy children)
Number of subjects: 30
Study: 8974104

Group type: EXPERIMENTAL
Intervention: rhGH (0.15 mg.kg‐1.d‐1)
Number of subjects: 20
Study: 1334821

Group type: EXPERIMENTAL
Intervention: Pravastatin (lipid-lowering agent)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 6145290

Group type: EXPERIMENTAL
Intervention: 80 mg propranolol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30277921

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (28 minutes of high-intensity exercises > 80% of maximum heart rate, 3 times a week for 12 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Combined training (60 minutes of walking at 70% of maximum heart rate and resistance exercises at 70% of one repetition maximum, 3 times a week for 12 weeks)
Number of subjects: 26
Study: 29486426

Group type: EXPERIMENTAL
Intervention: Researcher's evaluation findings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Program staff's evaluation findings
Number of subjects: 0
Study: 27694216

Group type: EXPERIMENTAL
Intervention: Dietary nitrate-rich beetroot juice (BR), 6.2 mmol of NO3- per shot, seven 70-ml shots consumed during the 48 hours after blood donation.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PL), seven 70-ml shots consumed during the 48 hours after blood donation.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dietary nitrate-rich beetroot juice (BR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 22
Study: 25364300

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich liquid drinks (CRLDs)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study: 21678140

Group type: EXPERIMENTAL
Intervention: MO(250) (moderate intensity, 2 × 6 × 250 m/rec 30 s/5 min at 85% of V(max))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: MO(500) (2 × 3 × 500 m/rec 1 min/5 min at 85% V(max))
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HI(250) (high intensity, 2 × 6 × 250 m/rec 30 s/5 min at 105% V(max))
Number of subjects: 13
Study: 20953528

Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mg/kg intravenous)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 8% Sevoflurane in 60% nitrous oxide and 40% oxygen with tidal-volume-breath (TVB)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 5% Sevoflurane in 60% nitrous oxide and 40% oxygen with tidal-volume-breath (TVB)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (before alfentanil)
Number of subjects: 90
Study: 18806686

Group type: EXPERIMENTAL
Intervention: Intranasal E2/NET (175 microg/275 microg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Oral E2/NET acetate (1 mg/0.5 mg)
Number of subjects: 82
Study: 15983301

Group type: EXPERIMENTAL
Intervention: Insulin and rosiglitazone 4 mg twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Insulin and placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Insulin and rosiglitazone
Number of subjects: 50
Study: 14613469

Group type: EXPERIMENTAL
Intervention: Glyburide-metformin tablets
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sulfonylurea plus metformin (SU+Met)
Number of subjects: 72
Study: 10877192

Group type: EXPERIMENTAL
Intervention: Fructose-1,6-diphosphate (FDP) infusion (5 g, 10%)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Glucose infusion (5 g)
Number of subjects: 45
Study: 8855984

Group type: EXPERIMENTAL
Intervention: ondansetron combined with dexamethasone
Number of subjects: 101

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: ondansetron only for 5 days after chemotherapy
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: anti-emetic treatment with dexamethasone
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: minimal tumour burden
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: low neuroticism
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: no history of motion sickness
Number of subjects: 101
Study: 1815521

Group type: EXPERIMENTAL
Intervention: Piroximone 25 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Piroximone 50 mg orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Piroximone intravenously
Number of subjects: 12
Study: 6869204

Group type: EXPERIMENTAL
Intervention: Indapamide 5 mg once daily for 14 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control period (placebo)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Indapamide treatment
Number of subjects: 6
Study: 29746301

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) early infant HIV testing
Number of subjects: 277

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) infant HIV testing
Number of subjects: 277
Study: 26474810

Group type: EXPERIMENTAL
Intervention: Ranolazine 1000 mg twice daily
Number of subjects: 2651

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2651
Study: 25757171

Group type: EXPERIMENTAL
Intervention: Clopidogrel (Listab) 75 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) or VKA
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clopidogrel (Listab)
Number of subjects: 60
Study: 22972862

Group type: EXPERIMENTAL
Intervention: Prior active tuberculosis
Number of subjects: 979

Group type: COMPARATOR
Intervention: No prior active tuberculosis
Number of subjects: 979
Study: 20583949

Group type: EXPERIMENTAL
Intervention: Dutogliptin 400 mg once daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily for 5 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dutogliptin 400 mg once daily and Metformin 1000 mg twice daily for 5 days
Number of subjects: 0
Study: 19047703

Group type: EXPERIMENTAL
Intervention: Electrodiagnostic testing (using sensory nerve conduction velocity) with stringent criteria
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Electrodiagnostic testing (using sensory nerve conduction velocity) with lax criteria
Number of subjects: 143

Group type: COMPARATOR
Intervention: Pretest probability assessment using CTS-6
Number of subjects: 143
Study: 15919161

Group type: EXPERIMENTAL
Intervention: Psychotherapy relapse prevention treatment
Number of subjects: 141

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Spontaneous cessation
Number of subjects: 141
Study: 12527674

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 230
Study: 11149105

Group type: EXPERIMENTAL
Intervention: Sodium ferric gluconate (Ferrlecit)
Number of subjects: 13